Home » More Patients Relapse in Gilead Hepatitis C Trial
More Patients Relapse in Gilead Hepatitis C Trial
Two more patients in a 10-patient segment of a mid-stage trial testing Gilead Sciences’ experimental hepatitis C drug GS-7977 had the virus return within four weeks of treatment.
Chicago Tribune
Chicago Tribune
Upcoming Events
-
07May
-
14May
-
30May